XML 60 R44.htm IDEA: XBRL DOCUMENT
v3.25.1

Schedule of Contractual Clinical Trials (Details) | Mar. 14, 2025 USD ($) Integer
--- | ---
Other Commitments [Line Items] |  |
Remaining financial contractual commitment | $ | $ 264,000 |
Subsequent Event [Member] | Phase 1b [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer |
Estimated Start Date | August 2024 |
Estimated End Date | December 2026 |
Number of Patients in Trial | Integer | 37 |
Expected Date | June 2026 |
Remaining financial contractual commitment | $ |  | [1]
Subsequent Event [Member] | Phase 1b Two [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with doxorubicin in advanced soft tissue sarcoma |
Estimated Start Date | June 2023 |
Estimated End Date | Recruitment completed September 2024 |
Expected Date | December 2025 |
Remaining financial contractual commitment | $ | $ 264,000 |
Subsequent Event [Member] | Phase 1b Two [Member] | Minimum [Member] |  |
Other Commitments [Line Items] |  |
Number of Patients in Trial | Integer | 9 |
Subsequent Event [Member] | Phase 1b Two [Member] | Maximum [Member] |  |
Other Commitments [Line Items] |  |
Number of Patients in Trial | Integer | 18 |
Subsequent Event [Member] | Randomized Phase 2 [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | Doxorubicin with or without LB-100 in advanced soft tissue sarcoma |
Number of Patients in Trial | Integer | 150 |
Remaining financial contractual commitment | $ |  | [1]
Subsequent Event [Member] | Clinical Trial Phase MD 1b 2 [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with dostarlimab in ovarian clear cell carcinoma |
Estimated Start Date | January 2024 |
Estimated End Date | December 2027 |
Number of Patients in Trial | Integer | 21 |
Expected Date | December 2026 |
Remaining financial contractual commitment | $ |  | [1]
[1] | The Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.

X
- Definition Clinical trial description. + References No definition available. + Details
Name: | LIXT_ClinicalTrialDescription
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual clinical trial period end date + References No definition available. + Details
Name: | LIXT_ContractualClinicalTrialPeriodEndDate
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual clinical trial period start date. + References No definition available. + Details
Name: | LIXT_ContractualClinicalTrialPeriodStartDate
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected date of preliminary efficacy signal. + References No definition available. + Details
Name: | LIXT_ExpectedDateOfPreliminaryEfficacySignal
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patient in trial. + References No definition available. + Details
Name: | LIXT_NumberOfPatientInTrial
Namespace Prefix: | LIXT_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseMD1b2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |